Projected Molecular Logic of Tumor Stratotypes under Ultrapurified Phospholipoproteic Platforms

Tumor responses to structurally active, non-cytotoxic platforms remain difficult to interpret using conventional pharmacodynamic paradigms. This study introduces a systems-level projection framework to infer intracellular signaling logic from phenotypic profiles induced by ultrapurified phospholipoproteic phospholipoproteic platforms (PLPCs). Unlike previous reports focused on functional classification, this work reanalyzes eight previously characterized tumor cell lines—classified as stimulatory, inhibitory, or neutral—and projects mechanistic hypotheses based on immune polarization (IFN-γ/IL-10 ratio), viability stability, and proliferation dynamics. By integrating immunometabolic markers and phospholipoproteic platforms proteomic content, we assigned each tumor line to a hypothetical signaling axis: IL-6/STAT3 in permissive Type I lines; p21/GADD45 and cGAS–STING in suppressive Type II lines; and SOCS3- or receptor-driven signaling insulation in inert Type III phenotypes. Proteomic enrichment in NAMPT, TIGAR, QSOX1, and FBP2 further supported non-lethal intracellular modulation consistent with metabolic or redox-based control. No cytotoxic markers were identified, and the proposed pathways are not confirmed mechanisms but interpretive mappings derived from structural and phenotypic data. This model does not claim new functional findings, but rather offers a logic-based interpretive layer to translate observed divergence into biologically plausible intracellular logic. The framework supports modular hypothesis generation, early prioritization of tumor models, and documentation of non-pharmacodynamic plqtform–tumor compatibility. It may serve as a complementary ana-lytical tier in immunotherapeutic development pipelines and offers value in regulatory contexts where direct molecular engagement cannot be demonstrated.